Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Hosted on MSN1d
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
pharmaphorum4d
Lilly invests another $3bn in its manufacturing network
Eli Lilly will spend ... device assembly, and packaging for medicines across multiple therapeutic areas," according to a company statement. Sales of both Mounjaro and Zepbound have been held ...
JD Supra3d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co ... versions of tirzepatide, Mounjaro® (for diabetes) and ...
pharmaphorum5d
Scotland first UK nation to clear Mounjaro use for obesity
Scotland has become the first country in the UK to back NHS use of Eli Lilly ... for Mounjaro by 25th June, with a final recommendation scheduled for the end of October. Lilly’s head of ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
The Motley Fool4d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...